AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10371003 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up questionnaire (1-4 years after treatment)
Number of subjects: 26
Study 8592096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of epinephrine at 12.5, 25, and 50 ng/(kg x min) for 1 hour each
Number of subjects: 21
Study 8592096 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 21
Study 10149510 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated cardiopulmonary bypass circuits
Number of subjects: 14
Study 10149510 — intervention group
Group type: COMPARATOR
Intervention: Nonheparin-coated cardiopulmonary bypass circuits
Number of subjects: 14
Study 6362341 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-150 mg Slow Apresoline once daily
Number of subjects: 118
Study 6362341 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylator phenotyping
Number of subjects: 118
Study 31610435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training
Number of subjects: 100
Study 31610435 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 100
Study 31610435 — intervention group
Group type: COMPARATOR
Intervention: Neutral placebo training
Number of subjects: 100
Study 31610435 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM training combined with oxytocin
Number of subjects: 100
Study 28371567 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin peglispro
Number of subjects: 388
Study 28371567 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 388
Study 26831302 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (0.6 mg for 7 days, 1.2 mg for 7 days, and 1.8 mg for 3 days)
Number of subjects: 21
Study 26831302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 26831302 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 21
Study 25110991 — intervention group
Group type: EXPERIMENTAL
Intervention: HCGM application for smartphones
Number of subjects: 63
Study 25110991 — intervention group
Group type: COMPARATOR
Intervention: Paging only
Number of subjects: 63
Study 22799482 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year after-school physical activity program (80 minutes of moderate-to-vigorous PA each school day)
Number of subjects: 574
Study 22799482 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 574
Study 20738780 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg intravenous infusion)
Number of subjects: 20
Study 20738780 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin (250 mg/h after an initial bolus of 250 mg)
Number of subjects: 20
Study 18439694 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 Gy in 12 fractions (ARM A)
Number of subjects: 60
Study 18439694 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy in five fractions (ARM B)
Number of subjects: 60
Study 18439694 — intervention group
Group type: COMPARATOR
Intervention: Both arms (ARM A and ARM B)
Number of subjects: 60
Study 15808246 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar injection of 5 ml of a 50:50 mixture of 4% lidocaine and 0.75% bupivacaine
Number of subjects: 61
Study 15808246 — intervention group
Group type: COMPARATOR
Intervention: Sub-Tenon's capsule injection of 5 ml of a 50:50 mixture of 4% lidocaine and 0.75% bupivacaine
Number of subjects: 61
Study 14623837 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cultures (BCs) performed
Number of subjects: 289
Study 10979930 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP/Hib and 7VPnC (group 2)
Number of subjects: 0
Study 10979930 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP and 7VPnC/Hib (group 3)
Number of subjects: 0
Study 10979930 — intervention group
Group type: COMPARATOR
Intervention: DTP/Hib (group 1)
Number of subjects: 0
Study 8741722 — intervention group
Group type: EXPERIMENTAL
Intervention: Complaints Management Training (CMT)
Number of subjects: 19
Study 8741722 — intervention group
Group type: COMPARATOR
Intervention: Anxiety Management Training (AMT)
Number of subjects: 19
Study 1313068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.6 mg/kg intravenously as a loading dose followed by 0.2 mg/kg every 6 h for 5 days
Number of subjects: 65
Study 1313068 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 65
Study 3874573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 39
Study 3874573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 31226457 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Modic changes (MCs) at baseline and 1-year follow-up after surgery
Number of subjects: 0
Study 31226457 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MCs
Number of subjects: 0
Study 31226457 — intervention group
Group type: COMPARATOR
Intervention: Patients with and without MCs reporting neck pain
Number of subjects: 0
Study 31226457 — intervention group
Group type: COMPARATOR
Intervention: Patients with and without MCs reporting disabling arm pain
Number of subjects: 0
Study 31226457 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of MCs
Number of subjects: 0
Study 29976234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitation only arm
Number of subjects: 4169
Study 29976234 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined WSH arm
Number of subjects: 4169
Study 29976234 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined WSH and Nutrition arm
Number of subjects: 4169
Study 27916752 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapy (including molecular target drugs)
Number of subjects: 0
Study 27916752 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange (PE)
Number of subjects: 0
Study 27916752 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 0
Study 25428346 — intervention group
Group type: EXPERIMENTAL
Intervention: Website B (interactive website with prescribed breakfast cereals)
Number of subjects: 180
Study 25428346 — intervention group
Group type: COMPARATOR
Intervention: Website A (standard advice on weight loss)
Number of subjects: 180
Study 23510752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (INT)
Number of subjects: 502
Study 23510752 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 502
Study 20506953 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior dynamic transpedicular stabilization
Number of subjects: 46
Study 20506953 — intervention group
Group type: COMPARATOR
Intervention: Posterior rigid transpedicular stabilization with fusion
Number of subjects: 46
Study 18155988 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-energy-density entrée (2.0 kcal/g)
Number of subjects: 77
Study 18155988 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-energy-density entrée (30% lower in energy density)
Number of subjects: 77
Study 18155988 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-energy-density entrée
Number of subjects: 77
Study 16437365 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-canal jejunum interposition (group A)
Number of subjects: 31
Study 16437365 — intervention group
Group type: COMPARATOR
Intervention: P pouch with Roux-en-Y esophagojejunostomy (group B)
Number of subjects: 31
Study 12927342 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic visual noise
Number of subjects: 0
Study 12927342 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial tapping
Number of subjects: 0
Study 12927342 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual interference with real objects
Number of subjects: 0
Study 12927342 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual noise
Number of subjects: 0
Study 12927342 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial tapping with same material
Number of subjects: 0
Study 12927342 — intervention group
Group type: EXPERIMENTAL
Intervention: Corsi test
Number of subjects: 0
Study 10787768 — intervention group
Group type: EXPERIMENTAL
Intervention: Information packet
Number of subjects: 536
Study 10787768 — intervention group
Group type: EXPERIMENTAL
Intervention: Action plan packet
Number of subjects: 536
Study 10787768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both packets
Number of subjects: 536
Study 10787768 — intervention group
Group type: COMPARATOR
Intervention: Neither packet
Number of subjects: 536
Study 8843498 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump treatment
Number of subjects: 358
Study 8843498 — intervention group
Group type: COMPARATOR
Intervention: Injection therapy
Number of subjects: 358
Study 1364273 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide (Tinset) tablets
Number of subjects: 57
Study 31462937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention aimed at increasing physical activity
Number of subjects: 0
Study 29770502 — intervention group
Group type: EXPERIMENTAL
Intervention: Father advocate intervention
Number of subjects: 66
Study 27075863 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 212
Study 27075863 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 212
Study 27075863 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg and 80 mg
Number of subjects: 212
Study 25312202 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal during the menstrual phase
Number of subjects: 36
Study 25312202 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal during the mid‐late luteal phase
Number of subjects: 36
Study 25312202 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation across menstrual phases
Number of subjects: 36
Study 25312202 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroticism impact on emotion regulation
Number of subjects: 36
Study 22460469 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (500 kcal) and resistance training (RT) 3 days/week
Number of subjects: 27
Study 22460469 — intervention group
Group type: COMPARATOR
Intervention: Minimal care
Number of subjects: 27
Study 19676097 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 246
Study 19676097 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 246
Study 19676097 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 246
Study 17914201 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% cyclosporine drops
Number of subjects: 30
Study 18607380 — intervention group
Group type: EXPERIMENTAL
Intervention: parent‐centered nutrition lifestyle program
Number of subjects: 165
Study 18607380 — intervention group
Group type: EXPERIMENTAL
Intervention: child‐centered physical activity skill development program
Number of subjects: 165
Study 18607380 — intervention group
Group type: EXPERIMENTAL
Intervention: both the programs
Number of subjects: 165
Study 18607380 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 165
Study 15384858 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase therapy
Number of subjects: 27
Study 15384858 — intervention group
Group type: COMPARATOR
Intervention: Ventriculostomy alone (Control)
Number of subjects: 27
Study 11320545 — intervention group
Group type: EXPERIMENTAL
Intervention: TPS
Number of subjects: 84
Study 11320545 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC
Number of subjects: 84
Study 11320545 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 84
Study 11320545 — intervention group
Group type: EXPERIMENTAL
Intervention: TPS and SCC
Number of subjects: 84
Study 9291051 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex sonography with intravenous ultrasound contrast agent (Levovist)
Number of subjects: 113
Study 9291051 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex sonography
Number of subjects: 113
Study 9291051 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced CT scanning
Number of subjects: 113
Study 8203337 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 36
Study 3555588 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg (C50)
Number of subjects: 211
Study 3555588 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg (HCTZ 25)
Number of subjects: 211
Study 3555588 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg and Hydrochlorothiazide 25 mg (C50/HCTZ 25)
Number of subjects: 211
Study 3555588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 31634877 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Therapy Management program (MTM)
Number of subjects: 392
Study 31634877 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 392
Study 30477922 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral zone (NZ) dentures
Number of subjects: 52
Study 30477922 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 52
Study 28988514 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic reafference training with increased tempo (fast group)
Number of subjects: 0
Study 28988514 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic reafference training with decreased tempo (slow group)
Number of subjects: 0
Study 28988514 — intervention group
Group type: COMPARATOR
Intervention: Control group with no manipulation of tempo
Number of subjects: 0
Study 25799402 — intervention group
Group type: COMPARATOR
Intervention: Placebo without exercise
Number of subjects: 409
Study 25799402 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D (800 IU/d) without exercise
Number of subjects: 409
Study 25799402 — intervention group
Group type: COMPARATOR
Intervention: Placebo and exercise
Number of subjects: 409
Study 25799402 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (800 IU/d) and exercise
Number of subjects: 409
Study 25799402 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 409
Study 25799402 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 409
Study 24332569 — intervention group
Group type: EXPERIMENTAL
Intervention: Benson's relaxation technique
Number of subjects: 86
Study 23159254 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warning labels
Number of subjects: 981
Study 23159254 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warning labels with graphic imagery
Number of subjects: 981
Study 23159254 — intervention group
Group type: COMPARATOR
Intervention: Text-only labels
Number of subjects: 981
Study 19019476 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 microg twice-daily
Number of subjects: 466
Study 19019476 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide with MET or MET and SU
Number of subjects: 466
Study 17955656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lianbai liquid (prevention group)
Number of subjects: 126
Study 17955656 — intervention group
Group type: COMPARATOR
Intervention: Control group I (advice only)
Number of subjects: 126
Study 17955656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lianbai liquid (treatment group)
Number of subjects: 126
Study 17955656 — intervention group
Group type: COMPARATOR
Intervention: Control group II (norfloxacin)
Number of subjects: 126
Study 15763649 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) comprising vincristine, etoposide, carboplatin, and cyclophosphamide followed by craniospinal RT 35 Gy/21 fractions with a posterior fossa boost 20 Gy/12 fractions.
Number of subjects: 68
Study 15763649 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) followed by craniospinal RT with a metastatic boost.
Number of subjects: 68
Study 15763649 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) prior to RT.
Number of subjects: 68
Study 12197849 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (81 mg daily for 7 days)
Number of subjects: 24
Study 12197849 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 7 days)
Number of subjects: 24
Study 9860148 — intervention group
Group type: EXPERIMENTAL
Intervention: M1 (generic mefloquine tablet)
Number of subjects: 18
Study 9860148 — intervention group
Group type: COMPARATOR
Intervention: M2 (reference mefloquine tablet)
Number of subjects: 18
Study 7611126 — intervention group
Group type: EXPERIMENTAL
Intervention: encainide‐flecainide
Number of subjects: 0
Study 7611126 — intervention group
Group type: EXPERIMENTAL
Intervention: moricizine
Number of subjects: 0
Study 7611126 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 2564948 — intervention group
Group type: COMPARATOR
Intervention: Nasal challenge with Trichophyton tonsurans extract (double-blind, placebo-controlled)
Number of subjects: 12
Study 2564948 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial provocation with Trichophyton tonsurans extract
Number of subjects: 12
Study 1263629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner with more frequent and longer patient visits, ordered more medications, less physician consultation.
Number of subjects: 0
Study 1263629 — intervention group
Group type: COMPARATOR
Intervention: Nurse practitioner who was more dependent on physicians for validation of her actions.
Number of subjects: 0
Study 30641815 — intervention group
Group type: EXPERIMENTAL
Intervention: Full ozone therapy plus standard regular diabetic foot ulcer treatment
Number of subjects: 200
Study 30641815 — intervention group
Group type: COMPARATOR
Intervention: Routine diabetic foot care
Number of subjects: 200
Study 30641815 — intervention group
Group type: EXPERIMENTAL
Intervention: Full ozone therapy
Number of subjects: 200
Study 29044006 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy combined with interferon
Number of subjects: 100
Study 29044006 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 100
Study 25536540 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundamental Integrative Training (FIT) group
Number of subjects: 41
Study 25536540 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 41
Study 25536540 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT group
Number of subjects: 41
Study 24422341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bhastrika pranayama (bellows breathing)
Number of subjects: 70
Study 24422341 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath awareness
Number of subjects: 70
Study 24422341 — intervention group
Group type: COMPARATOR
Intervention: Control session (non-yoga)
Number of subjects: 70
Study 21291323 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 million international units of IL-2 subcutaneously daily during the final 2 weeks of treatment interruption and the first week of treatment reinitiation (Arm A)
Number of subjects: 21
Study 21291323 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 million international units of IL-2 subcutaneously twice a day during the first 5 days of treatment reinitiation (Arm B)
Number of subjects: 21
Study 21291323 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 21
Study 19374158 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol and budesonide
Number of subjects: 50
Study 19374158 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol, budesonide and montelukast
Number of subjects: 50
Study 19374158 — intervention group
Group type: COMPARATOR
Intervention: salbutamol
Number of subjects: 50
Study 17268388 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BT-A) injections (3 successive doses to the calf muscle bilaterally at intervals of 3 to 4 months)
Number of subjects: 60
Study 17268388 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injections)
Number of subjects: 60
Study 15106100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination at 15 months
Number of subjects: 0
Study 15106100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination at 12 months
Number of subjects: 0
Study 15106100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination at 9 months
Number of subjects: 0
Study 15106100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination at 9 months (children of mothers born in or before 1963)
Number of subjects: 0
Study 15106100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination at 9 months, 12 months, and 15 months
Number of subjects: 0
Study 11168742 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride mouthrinse (ASF)
Number of subjects: 19
Study 11168742 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-free chlorhexidine
Number of subjects: 19
Study 11168742 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% triclosan solution
Number of subjects: 19
Study 11168742 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% triclosan solution
Number of subjects: 19
Study 11168742 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 19
Study 9597565 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg
Number of subjects: 12
Study 9597565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7890436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose triacetate (CTA) membranes
Number of subjects: 0
Study 7890436 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan (C) membranes
Number of subjects: 0
Study 7890436 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 3371085 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg) plus Amiloride (5 mg)
Number of subjects: 44
Study 3371085 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg) plus Amiloride (5 mg)
Number of subjects: 44
Study 30511430 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antibiotic paste with amoxicillin (TAPa)
Number of subjects: 50
Study 30511430 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antibiotic paste with cefaclor (TAPc)
Number of subjects: 50
Study 30511430 — intervention group
Group type: EXPERIMENTAL
Intervention: Double antibiotic paste (DAP)
Number of subjects: 50
Study 30511430 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antibiotic paste with doxycycline (TAPd)
Number of subjects: 50